Advertisement
 
Drug Discovery
Subscribe to Drug Discovery

The Lead

Phase 1 Results Positive for Tumor Vaccine

April 16, 2014 2:00 pm | News | Comments

Celldex Therapeutics Inc. announced that final data from its Phase 1 study of CDX-1401 (an off-the-shelf vaccine that targets dendritic cells) in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine. Read more...

Measles Drug Lowers Viral Load

April 16, 2014 2:00 pm | News | Comments

A novel antiviral drug may protect people infected with the measles from getting sick and...

Small Molecule Shows Potential in Advanced Cancers

April 16, 2014 1:34 pm | News | Comments

Cleveland BioLabs Inc. announced the achievement of all objectives in a Phase 1 clinical trial...

Drug Developers Using New Models, Methods to Boost Clinical Success Rates

April 16, 2014 11:05 am | News | Comments

Drug companies and their development partners who are seeking to increase clinical success rates...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

CBR Starts Cerebral Palsy Stem Cell Study

April 15, 2014 12:45 pm | News | Comments

Cord Blood Registry (CBR) announced the launch of an FDA-regulated clinical trial being conducted at The University of Texas Health Science Center at Houston to investigate two forms of stem cell therapy in children diagnosed with cerebral palsy. Read more...

Nanoparticles Target Cancer with Triple Threat

April 15, 2014 12:10 pm | News | Comments

Delivering chemotherapy drugs in nanoparticle form could help reduce side effects by targeting the drugs directly to the tumors, but it has been difficult to design particles that can carry any more than one or two drugs. Read more... 

Regenerating Muscle in Duchenne Muscular Dystrophy

April 15, 2014 11:04 am | News | Comments

A team of scientists has published details of how a class of drugs called “HDACis” drive muscle-cell regeneration in the early stages of dystrophic muscles, but fail to work in late stages. Read more...              

Advertisement

Potential New Way to Fight Malaria Drug Resistance

April 15, 2014 10:56 am | News | Comments

An anti-malarial treatment that lost its status as the leading weapon against the deadly disease could be given a new lease of life, with new research indicating it simply needs to be administered differently. Read more...        

Ex Vivo Data Supports Mast's Sickle Cell Treatment

April 14, 2014 2:19 pm | News | Comments

Mast Therapeutics Inc. announced that, in an ex vivo study, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. Read more...         

J&J is First Collaborator in Scripps’ Drug Discovery Initiative

April 14, 2014 1:48 pm | News | Comments

The Scripps Research Institute (TSRI) announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Read more...

Astellas European Foundation Awards 2014 Urology Grant

April 14, 2014 10:23 am | News | Comments

The Astellas European Foundation is announced the recipient of the 2014 Functional Urology and Uro-Gynecology Grant as Dr. Marianne Gamper for a project to be undertaken jointly in Austria and Switzerland to quantify marker levels to identify the potential relationship between Overactive Bladder Syndrome and Bladder Pain Syndrome/Interstitial Cystitis. Read more...

Brain Cell Find Points to New Therapies

April 14, 2014 9:57 am | News | Comments

Scientists have gained new understanding of the role played by a key molecule that controls how and when nerve and brain cells are formed- a process that allows the brain to develop and keeps it healthy. Read more...          

Advertisement

Cell Models Screen Novel Meds to Regulate Body Clock

April 11, 2014 1:53 pm | News | Comments

The consequences of modern life - shift work, cell phone addiction, and travel across time zones - all disturb internal clocks found in the brain where they regulate sleep and throughout the body where they regulate physiology and metabolism. Read more...

Expression of Tumor Suppressor Linked to Breast Cancer Survival

April 11, 2014 1:18 pm | News | Comments

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014. Read more...

Study Findings May Drive Parkinson’s Treatment Research

April 11, 2014 12:51 pm | News | Comments

Scientists at Johns Hopkins University and the Institute for Cell Engineering may have discovered how the most common genetic cause of Parkinson’s disease destroys brain cells and devastates many patients worldwide. Read more...  

Inhibiting Lactate Production Halts Tumor Growth

April 11, 2014 11:00 am | News | Comments

A research team has found that targeting the enzyme responsible for the final step of glucose metabolism not only halts tumor growth in non-small-cell lung cancer, but also leads to the regression of established tumors. Read more...       

Yeast Provides Genetic Clues to Drug Response

April 11, 2014 10:45 am | News | Comments

Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Read more...   

Advertisement

Promising Agents Burst Through 'Superbug' Defenses

April 10, 2014 3:26 pm | News | Comments

In the fight against "superbugs," scientists have discovered a class of agents called metallopolymers that can make some of the most notorious strains vulnerable to the same antibiotics that they once handily shrugged off. Read more...    

Breaking News: Drug Ups Survival in H1N1 Mice

April 10, 2014 12:00 pm | News | Comments

A new study reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus, a finding that paves the way for an urgently needed therapy. Read more...

New Vaccine Hope for Viral Cause of Birth Defects

April 10, 2014 10:25 am | News | Comments

Experts in infection and immunity have made a path-finding discovery that could lead to the development of a vaccine for a health-ravaging virus that affects around 50% of adults in the UK. Read more...              

Erytech Expands Tumor Starvation Development Portfolio

April 9, 2014 1:59 pm | News | Comments

Erytech Pharma announced the addition of a new product development candidate, ERY-MET, to the company’s tumor starvation product pipeline. Read more...                             

Phase 2 Efatutazone Trial Shows Challenge of Matching Treatment to Population

April 9, 2014 1:29 pm | News | Comments

Researchers hope that new work on a Phase 2 trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer will allow them to make better future use of the drug or other drugs in its class. Read more...      

Glucosamine Promotes Longevity in Mice

April 9, 2014 10:35 am | News | Comments

Feeding glucosamine to mice extended their lifespan by almost 10%, reflecting around eight additional years of human lifespan. Moreover, the supplement improved glucose metabolism in elderly mice, indicating that it may provide protection from diabetes. Read more...

Roche Snags New Biopharma Company for Antibiotics Deal

April 9, 2014 10:20 am | News | Comments

Spero Therapeutics LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche. Read more...                

Curis, Debiopharm Report Anti-Tumor Activity, Synergy with Debio 0932

April 8, 2014 1:39 pm | News | Comments

Curis Inc. and Debiopharm Group announced the presentation of data for Debio 0932 at the Annual Meeting of the AACR that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of NSCLC and RCC. Read more...

USPTO Grants Hovione a New Inhaler Patent

April 8, 2014 1:27 pm | News | Comments

Hovione announced that the United States Patent and Trademark Office has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione less than three years after the patent was filed and after just one Office Action– unusual speed for an inhaler application. Read more...

Calithera Glutaminase Inhibition Assay Shows Promise

April 8, 2014 1:17 pm | News | Comments

Calithera Biosciences, a clinical-stage biotechnology company focused on the development of novel cancer therapeutics, announced that data for its lead clinical candidate, CB-839, were featured in two presentations at the 2014 AACR Annual Meeting. Read more...

Antibody-Drug Conjugate Benefits Melanoma Patients in Phase 1

April 7, 2014 2:00 pm | News | Comments

The investigational drug DEDN6525A, which is a new member of a class of drugs called antibody-drug conjugates, was safe, tolerable, and showed hints of activity against three different forms of melanoma. Read more...          

CRT, Teva Collaboration IDs New Cancer Drug Candidate

April 7, 2014 10:41 am | News | Comments

Cancer Research Technology announced a successful outcome to their existing collaboration with Teva through the identification of a novel atypical Protein Kinase C (aPKC) inhibitor pre-clinical candidate, licensed by Teva. Read more...     

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading